Gonorrhea resistance testing may justify a higher price than current care assumes
Rising antimicrobial resistance in Neisseria gonorrhoeae has narrowed empiric treatment in the United States to ceftriaxone, a fragile position for a pathogen with a long record of adapting to every drug thrown at it. This modeling study asked a practical question with immediate policy consequences: how much can a resistance test cost and still make economic sense when its value is counted not only in today’s clinic visit, but also in the future burden of resistance and the expense of developing replacement antibiotics?
The answer depends heavily on what the test detects, how often resistance is present, and whether results arrive quickly enough to shape initial prescribing. The most conservative case produced very little room for a test price when ceftriaxone resistance was absent, a finding that matches the current US situation, where empiric ceftriaxone still remains the standard first-line choice for uncomplicated gonorrhea. Once ceftriaxone resistance rose, however, the ceiling changed dramatically. At 15% prevalence of ceftriaxone resistance, the per-episode cost-neutral threshold climbed to as much as $48 per test.
One result stood out sharply: a diagnostic strategy can look modest on paper and still become economically meaningful once resistance pressure starts to bite.
The model compared three testing strategies across a wide range of resistance scenarios: ciprofloxacin-only, ciprofloxacin plus ceftriaxone, and a triple-target panel that also included a novel drug A. Investigators built an individual-level stochastic simulation of gonorrhea diagnosis and treatment in the United States, folding in infection prevalence, symptom status, diagnostic accuracy, resistance profiles, treatment pathways, and partner management. Costs were calculated in 2025 US dollars. By design, the model stayed close to routine care: it examined how many dollars a resistance-guided strategy could absorb before it stopped breaking even against standard management.
Value shifted from immediate treatment savings to future resistance avoidance
The analysis separated economic value into three components: direct medical savings per episode, system-level costs tied to ceftriaxone resistance emergence among men who have sex with men, and avoided costs of antibiotic development. That structure matters because a resistance test can pay back in more than one way. It can spare an unnecessary broad-spectrum injection when ciprofloxacin is still active, preserve ceftriaxone when it is not, and potentially delay the need to fund an entirely new drug pipeline.
At a resistance pattern of 50% ciprofloxacin resistance and 5% ceftriaxone resistance, the population-weighted break-even threshold reached $7 per test for a ciprofloxacin-only assay, with a 95% uncertainty interval of $3 to $11. The corresponding threshold for the triple-target test was $13, with a 95% uncertainty interval of $8 to $19. In other words, the more information the assay gathered, the more value it could claim, but the price ceiling did not expand in a linear fashion. The added signal from a broader panel had to justify not just the laboratory burden of the test itself, but also the scale at which it would need to be deployed.
The economics became more striking in the subgroup of men who have sex with men, where the model extended beyond immediate episode-level savings. Once future resistance emergence and avoided antibiotic development costs were counted, the total per-test value rose to $31 to $114 for a single-target test and $73 to $106 for a triple-target test, depending on whether prescribing behavior changed when ceftriaxone resistance reached 5%.
Why timing determined the return on investment
Resistance-guided therapy only works if the result arrives early enough to steer the first treatment decision. When treatment was given before resistance results returned, value fell by more than 80%. That is not a trivial erosion; it converts a potentially useful diagnostic into a much weaker economic proposition because the main gain from targeted therapy comes from avoiding the wrong drug at the first visit.
That dependency is biologically and operationally intuitive. Gonorrhea can be transmitted to partners quickly, and a susceptible infection treated with ciprofloxacin can be cleared cheaply and effectively, while a resistant infection left on the wrong regimen risks ongoing infection, complications, and further spread. The same logic applies to ceftriaxone stewardship. If clinicians keep using the last-line agent for infections that do not need it, the pressure on the antimicrobial arsenal only intensifies. A rapid resistance result interrupts that cycle at the point of care.
The study also makes a quieter point about diagnostics policy. How a test is used can matter as much as what it detects. A triple-target panel can appear less attractive in some scenarios because its longer-term benefit requires testing more people, and broader assays only pay off if they are integrated into workflows that can act on the result immediately. A sophisticated panel with slow turnaround may still underperform a simpler test delivered in the same clinical encounter.
Stewardship value extends beyond the individual case
Gonorrhea remains a major public health problem, with an estimated 82 million incident cases globally each year. In women, inadequate treatment can lead to pelvic inflammatory disease, chronic pelvic pain, ectopic pregnancy, tubal infertility, and disseminated infection. In men, epididymitis and disseminated infection add their own clinical and economic burden. These downstream outcomes are precisely why resistance testing should not be priced only against the drug it replaces. The larger question is whether it can prevent avoidable complications and slow the erosion of effective therapy across the population.
The study’s framing is especially relevant as two new antimicrobials, zoliflodacin and gepotidacin, begin to enter the market. New agents are necessary, but history offers a warning: every new gonorrhea antibiotic faces the same evolutionary pressure that has already reduced older regimens to fragments of their former utility. A resistance-guided strategy is one way to preserve the lifespan of both old and new drugs, reducing the chance that health systems will have to pay repeatedly for replacement therapies.
The analysis has clear limits. Resistance results were assumed to be available during the same clinical visit, the model did not include onward transmission, and it did not capture co-resistance between antibiotics. Longer-term value was estimated only for men who have sex with men. Even so, the economic signal was substantial enough to support investment in testing infrastructure, especially when reimbursement decisions are made under pressure to justify both near-term spending and long-term stewardship.
The central policy implication is concrete: a gonorrhea resistance test does not need to be cheap to be valuable. Its worth grows when it can redirect therapy at the first visit, protect ceftriaxone from unnecessary use, and defer the larger costs of resistance-driven drug replacement.
- • PLOS Medicine article DOI 10.1371/journal.pmed.1005073: https://doi.org/10.1371/journal.pmed.1005073
- • Zenodo archive DOI 10.5281/zenodo.22093354: https://doi.org/10.5281/zenodo.22093354
- • Zenodo archive DOI 10.5281/zenodo.22093355: https://doi.org/10.5281/zenodo.22093355